Expansion Of Pam50 Efficacy
ID U-6516
Category Diagnostics
Subcategory Biomarkers
Researchers
Brief Summary
Algorithms and biomarkers that expand the PAM50 test treatment range.
Problem Statement
The PAM50 test characterizes tumors using gene profiles that have demonstrated clinical success. However, PAM50 obfuscates subtler cross-cutting characteristics of tumor samples, limiting the test to specific breast cancer subtypes.
Technology Description
New algorithms and biomarkers categorize tumors without assuming tumor subtype exclusivity. This information can be used to better predict patients’ survival rates and response to paclitaxel treatment. When used in conjunction with a novel breast cancer locus, the new algorithms and biomarkers enable more accurate PAM50 testing and enhance gene mapping possibilities.
Stage of Development
Proof of Concept
Benefit
- Broadens the PAM50 tumor subtype range for treatment.
- Identifies new susceptibility genes.
- Predicts chemotherapy response.
- Enhances gene mapping possibilities
Publications
Madsen MJ, Knight S, Sweeney C, et al. Reparameterization of PAM50 Expression Identifies Novel Breast Tumor Dimensions and Leads to Discovery of a Genome-Wide Significant Breast Cancer Locus at 12q15. Cancer Epidemiol Biomarkers Prev. 2018;27(6):644-652. doi:10.1158/1055-9965.EPI-17-0887
Contact Info
Jason Young
(801) 587-0519
jason.r.young@utah.edu
